Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion type Assertion NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_head.
- NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_provenance.
- NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion evidence source_evidence_literature NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_provenance.
- NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion SIO_000772 19891708 NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_provenance.
- NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion wasDerivedFrom befree-20140225 NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_provenance.
- NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion wasGeneratedBy ECO_0000203 NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_provenance.